NEW YORK (AP) — Stocks that traded heavily or had substantial price changes Wednesday:
United Natural Foods Inc., down $6.36 to $34.26.
The natural and organic food company reported disappointing fiscal third-quarter revenue.
Comtech Telecommunications Corp., down $3.53 to $22.13.
The communications company gave investors a weak revenue forecast for the year.
Lordstown Motors Corp., up 1 cent to $11.23.
The electric truck company warned investors that it needs to raise more money.
Campbell Soup Co., down $3.20 to $45.92.
The maker of canned soup, Pepperidge Farm cookies and V8 juice reported disappointing fiscal third-quarter financial results.
Merck & Co., up $1.64 to $74.04.
The drug developer signed a supply agreement with the U.S. and Canada for a potential COVID-19 treatment.
Vertex Pharmaceuticals Inc., up $2.43 to $213.56.
The drug developer received FDA approval for expanded use of its cystic fibrosis drug Trikafta in children.
AbbVie Inc., up $1.66 to $114.
The biotechnology company and Caraway Therapeutics are collaborating on treatments for Parkinson’s disease and other neurodegenerative disorders.
Ferrari NV, down $6.64 to $212.18.
Luxury sports carmaker Ferrari tapped Benedetto Vigna, an Italian executive at Europe’s largest semiconductor chipmaker, as its new CEO.
Before you consider Vertex Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.
While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
